Beyond The "Blueprint": The Next Stage For US HHS Drug Price Policy
Executive Summary
Upcoming transition in HHS drug pricing policy staff reinforces the Trump Administration's shift away from the 2018 "Blueprint” and towards engaging with bipartisan Congressional legislation – and spotlighting executive action as coming from the White House in the context of the upcoming Presidential campaign.
You may also be interested in...
Accelerated Approval For Medicare Coverage? FDA Model Could Be Useful For Value-Based Agreements
Centers for Medicare & Medicaid Innovation could enable outcomes-based contracting for novel, 'curative' therapies follow something like the FDA’s Accelerated Approval model, former top HHS official suggests.
Trump’s Maximum Pressure Campaign On US Drug Pricing
President Trump isn’t going to let the Democrats own the drug pricing debate heading into the 2020 elections, so biopharma companies can look forward to many more headlines like the importation announcement on 31 July. When will it end?
US Drug Pricing Debate Enters Critical Phase: Two Visions For 2021
If the Senate's bipartisan price reform proposal is enacted into law this year, the drug pricing agenda for the next Administration will likely be set: implementing a host of changes to Medicare Part B, Part D and Medicaid. But if it fails, then more direct price negotiation measures will likely be the new starting point.